BIOPHARMA
By
Can AI Reveal the Hidden Biology of Cancer? Aitia and Gustave Roussy Join Forces to Decode Disease Causality for Next-Gen Therapies
Key Highlights: AI Collaboration to Decode Cancer ComplexityIn a bold step to redefine cancer treatment, Aitia, a leader…
Is Juvenescence’s Acquisition of Ro5 the Key to Unlocking AI-Driven Longevity Therapies in 2025?
Key Insights Juvenescence Acquires Ro5 to Bolster AI Capabilities in Drug DiscoveryJuvenescence Limited, a clinical-stage AI-enabled biotech company,…
Can AI Turn Biobank Data into Precision Drug Discovery Gold? Inside the Elucidata–Sapien Biosciences Alliance
Key Highlights Transforming Biobanks into AI-Driven EnginesElucidata, a U.S.-India based AI pioneer in life sciences, and Sapien Biosciences,…
How Will Axxam and Molecular Health’s AI-Powered Alliance Accelerate Target Discovery and De-Risk Drug Development for Pharma?
Key Highlights: Strategic Collaboration Targets Early Drug Discovery BottlenecksAnnounced on June 4, 2025, Molecular Health and Axxam have…
Can Catalio Capital’s $400 Million AI-Driven Life Sciences Fund Ignite a New Era of Biomedical Innovation Despite a Slow VC Market?
Key Takeaways Resilience in a Cooling VC ClimateCatalio Capital Management has successfully closed its fourth Nexus Fund at…
Is Portal Biotech’s $35M Series A Set to Redefine Proteomics With the World’s First AI-Powered Full-Length Single-Molecule Protein Sequencer?
Key Takeaways Transforming Protein Sequencing With AI and Nanopore InnovationPortal Biotech, a London-based pioneer in proteomics, is aiming…
